Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Activated protein C [drotrecogin-alfa] in acute stroke trial

Trial Profile

Activated protein C [drotrecogin-alfa] in acute stroke trial

Phase of Trial: Phase II

Latest Information Update: 28 Oct 2016

At a glance

  • Drugs Drotrecogin alfa (Primary)
  • Indications Embolism and thrombosis; Stroke
  • Focus Adverse reactions
  • Acronyms APCAST
  • Most Recent Events

    • 16 Dec 2010 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
    • 10 Dec 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 11 Oct 2009 Planned end date (Aug 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top